Tech Company Financing Transactions
Aquinnah Pharmaceuticals Funding Round
AbbVie Biotech Ventures and Pfizer Venture Investments joined a $10 million capital raise for Aquinnah Pharmaceuticals. The financing closed on 4/25/2017.
Transaction Overview
Company Name
Announced On
4/25/2017
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
AbbVie Biotech Ventures (Scott Brun)
Pfizer Venture Investments (Morris Birnbaum)
Proceeds Purpose
We discovered that RNA binding proteins play a critical role in brain deterioration, cognitive loss and life expectancy reduction in mouse models of Alzheimer's disease. Targeting these pathways are expected to yield new therapies for the treatment of Alzheimer's disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
610 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Not Recorded
Overview
Aquinnah Pharmaceutical's approach is unique by integrating human genetic, human pathology and cellular biology R&D expertise, towards the development of a new therapeutic approach. Our approach has the potential to treat the majority of patients with ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig's disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Glenn Larsen
Chief Financial Officer
Daniel Geffken
Chief Scientific Officer
Benjamin Wolozin
VP - General Counsel
Joshua Fox
VP - R & D
Travis Wager
Browse more venture capital transactions:
Prev: 4/25/2017: ClearOne Advantage venture capital transaction
Next: 4/25/2017: K2 Intelligence venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records on this site are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs